JP2023528139A - ヒト核因子e2関連因子2の発現ベクター及び発現ベクターの適用 - Google Patents
ヒト核因子e2関連因子2の発現ベクター及び発現ベクターの適用 Download PDFInfo
- Publication number
- JP2023528139A JP2023528139A JP2022559360A JP2022559360A JP2023528139A JP 2023528139 A JP2023528139 A JP 2023528139A JP 2022559360 A JP2022559360 A JP 2022559360A JP 2022559360 A JP2022559360 A JP 2022559360A JP 2023528139 A JP2023528139 A JP 2023528139A
- Authority
- JP
- Japan
- Prior art keywords
- nrf2
- vector
- cells
- protein
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000007561 NF-E2-Related Factor 2 Human genes 0.000 title claims abstract description 28
- 108010071382 NF-E2-Related Factor 2 Proteins 0.000 title claims abstract description 28
- 239000013604 expression vector Substances 0.000 title abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 70
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 claims abstract description 68
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 claims abstract description 63
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 38
- 239000002773 nucleotide Substances 0.000 claims abstract description 30
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 30
- 210000004027 cell Anatomy 0.000 claims description 102
- 239000013598 vector Substances 0.000 claims description 81
- 210000001328 optic nerve Anatomy 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 36
- 230000014509 gene expression Effects 0.000 claims description 33
- 241000700605 Viruses Species 0.000 claims description 27
- 208000003098 Ganglion Cysts Diseases 0.000 claims description 25
- 208000005400 Synovial Cyst Diseases 0.000 claims description 25
- 201000010099 disease Diseases 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 238000002360 preparation method Methods 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 15
- 210000003994 retinal ganglion cell Anatomy 0.000 claims description 15
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 14
- 208000001992 Autosomal Dominant Optic Atrophy Diseases 0.000 claims description 9
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 claims description 9
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 claims description 9
- 230000001965 increasing effect Effects 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 208000010412 Glaucoma Diseases 0.000 claims description 7
- 208000028389 Nerve injury Diseases 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 230000008764 nerve damage Effects 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 claims description 5
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims description 5
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 230000003213 activating effect Effects 0.000 claims description 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 230000001413 cellular effect Effects 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 230000006907 apoptotic process Effects 0.000 claims description 3
- 230000003833 cell viability Effects 0.000 claims description 3
- 230000002000 scavenging effect Effects 0.000 claims description 3
- 210000000349 chromosome Anatomy 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 abstract description 28
- 102000039446 nucleic acids Human genes 0.000 abstract description 17
- 108020004707 nucleic acids Proteins 0.000 abstract description 17
- 238000003259 recombinant expression Methods 0.000 abstract description 2
- 239000013646 rAAV2 vector Substances 0.000 description 40
- 239000013612 plasmid Substances 0.000 description 33
- 241000699670 Mus sp. Species 0.000 description 32
- 210000001525 retina Anatomy 0.000 description 24
- 210000002592 gangliocyte Anatomy 0.000 description 20
- 241000702421 Dependoparvovirus Species 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 108091028043 Nucleic acid sequence Proteins 0.000 description 18
- 210000001508 eye Anatomy 0.000 description 18
- 239000013603 viral vector Substances 0.000 description 18
- 239000003814 drug Substances 0.000 description 16
- 229940079593 drug Drugs 0.000 description 16
- 230000002207 retinal effect Effects 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 15
- 241000283973 Oryctolagus cuniculus Species 0.000 description 15
- 230000003612 virological effect Effects 0.000 description 13
- 239000013607 AAV vector Substances 0.000 description 12
- 239000007924 injection Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 102000040430 polynucleotide Human genes 0.000 description 11
- 108091033319 polynucleotide Proteins 0.000 description 11
- 239000002157 polynucleotide Substances 0.000 description 11
- 239000007788 liquid Substances 0.000 description 10
- 238000010186 staining Methods 0.000 description 10
- 239000003623 enhancer Substances 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 239000012634 fragment Substances 0.000 description 8
- 238000005457 optimization Methods 0.000 description 8
- 238000004806 packaging method and process Methods 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 241000701022 Cytomegalovirus Species 0.000 description 7
- 241000701161 unidentified adenovirus Species 0.000 description 7
- 101150027545 GRM6 gene Proteins 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 210000000608 photoreceptor cell Anatomy 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000004410 intraocular pressure Effects 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 208000030768 Optic nerve injury Diseases 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 101150008375 Pou4f1 gene Proteins 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000003125 immunofluorescent labeling Methods 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 3
- 101150044789 Cap gene Proteins 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 3
- 108700010070 Codon Usage Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 210000000411 amacrine cell Anatomy 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000005252 bulbus oculi Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 238000010188 recombinant method Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 101150066583 rep gene Proteins 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 2
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 2
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 2
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 238000011767 DBA/2J (JAX™ mouse strain) Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 101000821100 Homo sapiens Synapsin-1 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 241000713311 Simian immunodeficiency virus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100021905 Synapsin-1 Human genes 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 208000028659 discharge Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 206010014801 endophthalmitis Diseases 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 210000002287 horizontal cell Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000001232 limbus corneae Anatomy 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000002597 off-bipolar cell Anatomy 0.000 description 2
- 210000001743 on-bipolar cell Anatomy 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- -1 restrin Proteins 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 1
- 241000649045 Adeno-associated virus 10 Species 0.000 description 1
- 241000649046 Adeno-associated virus 11 Species 0.000 description 1
- 241000649047 Adeno-associated virus 12 Species 0.000 description 1
- 241000300529 Adeno-associated virus 13 Species 0.000 description 1
- 241000714230 Avian leukemia virus Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- 108091029523 CpG island Proteins 0.000 description 1
- 108091029430 CpG site Proteins 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 102100035902 Glutamate decarboxylase 1 Human genes 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000575685 Homo sapiens Synembryn-B Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 101710118186 Neomycin resistance protein Proteins 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100026014 Synembryn-B Human genes 0.000 description 1
- 101150052863 THY1 gene Proteins 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 102000014823 calbindin Human genes 0.000 description 1
- 108060001061 calbindin Proteins 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 108010024847 glutamate decarboxylase 1 Proteins 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000014726 immortalization of host cell Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 108010038450 metabotropic glutamate receptor 6 Proteins 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000005709 nerve cell growth Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 101150075804 nqo1 gene Proteins 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000004254 retinal expression Effects 0.000 description 1
- 210000001210 retinal vessel Anatomy 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
(a)配列番号1に記載のヌクレオチド配列、及び
(b)配列番号1に記載のヌクレオチド配列と95%以上、好ましくは98%以上、より好ましくは99%以上の同一性を有するヌクレオチド配列、からなる群から選択される、ヌクレオチド配列を提供する。
(a)細胞の抗炎症反応または抗酸化反応を活性化すること、
(b)神経節細胞の生存率を高めること、
(c)神経節細胞のアポトーシスを防止するまたは遅延させること、
(d)網膜神経節細胞におけるNrf2遺伝子の安定した高い発現を引き起こすこと、及び
(e)疾患細胞からフリーラジカルを除去すること
からなる群から選択される1つ以上の項目のためにも使用される。
本開示をより容易に理解することができるように、ある特定の用語が最初に定義される。本出願で使用される場合、本明細書で別途明確に記載されない限り、以下の用語は各々、以下に付与される意味を有する。他の定義は、本出願を通じて記載される。
アデノ随伴ウイルス(adeno-associated virus、AAV)、別名、アデノ随伴ウイルス(adeno associated virus)は、Parvoviridae科のディペンドウイルス属に属し、これまでに発見された最も単純な構造を有する一本鎖DNA欠損ウイルスのクラスであり、その複製にはヘルパーウイルス(通常、アデノウイルス)の関与が必要である。これは、2つの逆方向末端反復(ITR)におけるcap遺伝子及びrep遺伝子をコードする。ITRは、ウイルス複製及びパッケージングにおいて決定的な役割を果たす。cap遺伝子はウイルスカプシドタンパク質をコードし、rep遺伝子はウイルスの複製及び組み込みに関与する。AAVは、様々な細胞に感染することができる。
本発明によって解決されるべき技術的課題は、先行技術における核因子E2関連因子2(Nrf2)タンパク質のトランスフェクション効率の低さ及び治療効果の低さという技術的欠陥を克服することである。本発明は、核因子E2関連因子2(Nrf2)タンパク質ならびにその調製方法及び適用を提供する。本発明の最適化されたNrf2遺伝子配列(配列番号1)がNrf2タンパク質の発現をより効率的にし、それにより、より多くのNrf2タンパク質が患者の視神経節細胞において生理的役割を果たすことが研究により見出される。
本発明は、Nrf2ヌクレオチド配列の最適化(配列番号1に記載のもの、本発明では最適化Nrf2遺伝子/核酸と称される)を行い、この配列は特別に最適化され、それ故に、図1aに示されるように、転写効率及び翻訳効率が著しく改善され、ここで、最適化Nrf2配列と非最適化Nrf2配列の相同性は75%である。
本発明は、本発明の最適化Nrf2コード配列を含むNrf2タンパク質の発現ベクターも提供する。
本発明は、(a)請求項2に記載のベクターと、(b)薬学的に許容される担体または賦形剤とを含む調製物または組成物を提供する。
(a)細胞の抗炎症反応または抗酸化反応を活性化すること、
(b)神経節細胞の生存率を高めること、
(c)神経節細胞のアポトーシスを防止するまたは遅延させること、
(d)網膜神経節細胞におけるNrf2遺伝子の安定した高い発現を引き起こすこと、及び
(e)疾患細胞からフリーラジカルを除去すること
からなる群から選択される1つ以上の項目のために使用される。
1.本発明の組換えヒト核因子E2関連因子2(Nrf2)タンパク質のコード遺伝子配列は、特別に最適化されている。Nrf2の非最適化DNAコード配列と比較して、転写効率及び翻訳効率が有意に改善され、コドン使用がより効率的になり、最適化配列のNrf2タンパク質発現レベルが有意に改善され、生物学的活性が高い。
1.1 ベクターの構築
ヒトNrf2ヌクレオチド配列(配列番号2に記載のもの)を得た後、Nrf2ヌクレオチド配列最適化(配列番号1に記載のもの)を行った。核酸配列最適化には、コドン使用バイアス、発現を助長しない二次構造(ヘアピン構造など)の排除、GC含有量、CpGジヌクレオチド含有量、mRNA二次構造、潜在スプライス部位、初期ポリアデニル化部位、内部リボソーム進入及び結合部位、ネガティブCpGアイランド、RNA不安定性領域、反復(直接反復、逆方向反復など)、ならびにクローニングに影響を及ぼし得る制限部位の変化が含まれる。最適化配列(配列番号1)にCla I及びXba Iの2つの制限部位を付加するか、または新規遺伝子及びpAAVプラスミドベクターに設計したプライマーでのPCR増幅によって生成された生成物を、それぞれ、Cla I及びXba I二重酵素消化に供し、その後、消化産物を回収し、T4 DNAリガーゼで一晩ライゲーションし、その後、ライゲーション産物をコンピテント細胞に形質転換して、組換えpAAV-Nrf2を得た。細菌液体シーケンシングのために単一のクローンを選択し、シーケンシングによって得た配列を配列アラインメント分析に供して、エンハンサー/プロモーター、遺伝子配列、ポリA、及びウイルスパッケージングITR配列を含む、図7に示される、正しい配列を有する組換えアデノ随伴ウイルスプラスミドpAAV-Nrf2の取得に成功した。図7a、図7b、図7c、及び図7dは、それぞれ、pAAV-CMV-Nrf2_天然プラスミド、pAAV-CMV-Nrf2_最適化プラスミド、pAAV-CAG-Nrf2_最適化プラスミド、及びpAAV-SYN-Nrf2_最適化プラスミドのプロファイルである。
pAdHelperプラスミド、pAAV-r2c5プラスミド、pAAV-Nrf2プラスミドを293T細胞にトランスフェクトし(225cm2の細胞培養フラスコに播種)、細胞を48時間後に採取した。細胞をPBS中に再懸濁し、3回凍結融解した。
クロロホルム処理-PEG/NaCl析出-クロロホルム抽出の3つのステップを使用してrAAV2/2-Nrf2ウイルスを単離し、濃縮し、精製した。全回収率=最終生成物中のウイルス粒子の数/出発材料中のウイルス粒子の数。
実験材料:SYBR II(takara)、標的断片プライマー(20uM)、ウイルスをパッケージングするための標的プラスミド(既知の濃度)、試験するウイルス、8チューブPCRストリップ(Bio-red)。
2.1 マウスの眼の硝子体への組換えアデノ随伴ウイルスの注射
マウスを5%抱水クロラールの腹腔内注射により麻酔し、マウスを麻酔した後、マウスの眼の外側及び眼球を洗浄し、消毒した。インスリン針を使用してマウスの強角膜縁の下に穴を開け、組換えアデノ随伴ウイルスベクター及び薬学的に許容される担体または賦形剤からなる1~2μlの組換えアデノ随伴ウイルス調製物をマイクロシリンジで硝子体内注射した。マウスを、自由に食餌させた標準環境で維持し、マウスの眼の状態を毎日観察した。
投薬の3週間後、眼球を取り出した状態で脊椎を折ることによってマウスを屠殺し、網膜を氷上で速やかに剥離し、液体窒素下で保存した。RIPA緩衝液で網膜組織を溶解した後、Nrf2タンパク質の発現レベルをWB実験によって検出した。図1aは、rAAV2/2-Nrf2_天然ウイルス及びrAAV2/2-Nrf2_最適化ウイルスがマウスの網膜に感染した後のタンパク質レベルの比較であり、配列最適化後のベクターのタンパク質発現レベルは、最適化前の5倍以上高い。
3.1 マウス急性視神経損傷モデル
成体BL6/C57マウスを5%抱水クロラールの腹腔内注射によって麻酔した。マウスを動物手術台上に固定し、眼皮膚をヨードフォアで消毒した。眼球の結膜組織を強角膜縁から強膜に沿って切断し、眼球と結膜との間で鈍的後方分離(bluntly backward separation)を行い、脊椎筋肉を露出させた。この分離により視神経が完全に露出し、その後、視神経を、鉗子の終端を幅1mmに保った状態で逆自動ロック式エルボー鉗子を用いて、眼球の2mm後方で10秒間保持した。術後観察を行い、眼軟膏を使用して、眼底出血、水晶体損傷、及び眼内炎症を有するマウスを除外した。
5匹の非モデル化マウスを正常群として使用した。モデル化に成功したマウスを、硝子体内注射のために3つの群に分けた。対照群にrAAV2/2-mCherryウイルスを注射し(n=7)、実験群AにrAAV2/2-Nrf2_天然ウイルスを注射し(n=8)、実験群BにrAAV2/2-Nrf2_最適化ウイルスを注射した(n=8)。
脊椎を折ることによってマウスを屠殺し、眼球を取り出し、固定剤で20分間固定し、その後、網膜を剥離し、4枚の花弁状の花びらに切断し、4%パラホルムアルデヒドに4℃で一晩固定した。得られた材料を1%TritonX-100で2時間穿孔し、ブロッキング溶液で1時間ブロックした。その後、得られた材料を、一次抗体としてTUJ1抗体(神経節細胞特異的抗体)と4℃で一晩インキュベートし、二次抗体と室温で2時間インキュベートした。核をDAPIで15分間染色した後、載置した。
4.1 DBA/2Jマウスの硝子体内注射
7ヶ月齢のDBA/2Jマウス(眼内圧>18mmHg)を3つの群に分け、6匹のマウスにモデル群としてPBSを注射し、他の2つの群に、それぞれ、rAAV2/2-CAG-Nrf2_最適化ウイルス(n=7)及びrAAV2/2-SYN-Nrf2_最適化ウイルス(n=7)を単眼硝子体内注射した。同じ月齢の5匹のC57/BL6マウスを正常群として使用した。
眼底検査及び眼内圧検査を術後3~5日毎に行った。すべてのマウスの眼に明らかな異常は認められず、結膜充血、分泌、眼内炎、または眼内圧の明らかな変化は認められなかった。
投薬の5ヶ月後、脊椎を折ることによってマウスを屠殺し、網膜を神経節細胞の免疫蛍光染色及び計数のために採取した。図3に示される結果は、モデル群のマウスにおける生存神経節細胞の密度(971±146 RGC/mm2、図3b)が正常群(1506±152 RGC/mm2、図3a)よりも有意に低かった(P<0.05)ことを示す。rAAV2/2-CAG-Nrf2_最適化群(1426±179 RGC/mm2、図3c)及びrAAV2/2-SYN-Nrf2_最適化群(1384±88 RGC/mm2、図3d)における神経節細胞の密度は、モデル群(1506±152 RGC/mm2、図3b)と比較して有意に増加し(P<0.05)、薬物群のモデル化マウスにおける網膜神経節細胞に対する保護効果を示した。しかしながら、rAAV2/2-CAG-Nrf2_最適化群とrAAV2/2-SYN-Nrf2_最適化群との間に有意差はなかった。図3eは、各群におけるマウスの単位網膜面積当たりのRGC細胞数の統計的結果を示す。
眼球を、凍結切片及びNrf2抗体での免疫蛍光染色を行うために採取した。網膜におけるrAAV2/2-CAG-Nrf2_最適化及びrAAV2/2-SYN-Nrf2_最適化の発現レベルを検出した。図4に示される結果は、マウスの網膜をrAAV2/2-CAG-Nrf2_最適化に感染させた後、Nrf2タンパク質が網膜神経節細胞のみならず、双極細胞及びアマクリン細胞でも強く発現したことを示す(図4a)。しかしながら、Nrf2タンパク質は、rAAV2/2-SYN-Nrf2_最適化による網膜感染後では、網膜神経節細胞で主に発現し(図4b)、より高い特異性を有した。
5.1 ウサギ眼への硝子体内注射
27匹のニュージーランド白ウサギを、PBS群、実験群A、及び実験群Bを含む3つの群に分け、その後、50uLの1×1012vg/mlのrAAV2/2-CAG-Nrf2_最適化及びrAAV2/2-SYN-Nrf2_最適化を、それぞれ、角膜縁から3mmに位置する毛様体扁平部を穿刺した後に硝子体内注射して、硝子体腔に入れた。
3つの群のウサギを、術後1、3、7、及び30日目に細隙灯及び眼内圧に関して検査した。すべてのウサギに明らかな異常は認められず、結膜充血、分泌、眼内炎、または眼内圧の増加は認められなかった。術後1ヶ月のウサギの眼底写真の結果を図5に示す。対照群におけるウサギの眼底(図5a)と比較して、実験群A(図5b)及び実験群B(図5c)におけるウサギの網膜血管及び視神経に明らかな合併症または損傷はなく、通常の標準硝子体内注射が明らかな炎症反応または他の合併症を引き起こさないことを示した。
ウサギ眼球切片のH&E染色の結果は、実験群A(図6b)、実験群B(図6c)、及び対照群(図6a)における網膜神経節細胞数が基本的に同じであり、かつ階層構造が完全であることを示し、Nrf2_最適化組換え遺伝子が安全であり、網膜に損傷を与えないことを示した。
pAdHelperプラスミド、pAAV-r2c2プラスミド、pAAV-Nrf2プラスミドを293T細胞にトランスフェクトし(225cm2の細胞培養フラスコに播種)、細胞を48時間後に採取した。細胞をPBS中に再懸濁し、3回凍結融解した。
投薬の5ヶ月後、脊椎を折ることによってマウスを屠殺し、網膜を神経節細胞の免疫蛍光染色及び計数のために採取した。図3に示される結果は、モデル群のマウスにおける生存神経節細胞の密度(971±146 RGC/mm2、図3b)が正常群(1506±152 RGC/mm2、図3a)よりも有意に低かった(P<0.05)ことを示す。rAAV2/2-CAG-Nrf2_最適化群(1426±179 RGC/mm2、図3c)及びrAAV2/2-SYN-Nrf2_最適化群(1384±88 RGC/mm2、図3d)における神経節細胞の密度は、モデル群(971±146 RGC/mm2、図3b)と比較して有意に増加し(P<0.05)、薬物群のモデル化マウスにおける網膜神経節細胞に対する保護効果を示した。しかしながら、rAAV2/2-CAG-Nrf2_最適化群とrAAV2/2-SYN-Nrf2_最適化群との間に有意差はなかった。図3eは、各群におけるマウスの単位網膜面積当たりのRGC細胞数の統計的結果を示す。
Claims (10)
- ヒト核因子E2関連因子2(Nrf2)タンパク質をコードするヌクレオチド配列であって、
(a)配列番号1に記載のヌクレオチド配列、及び
(b)配列番号1に記載のヌクレオチド配列と95%以上、好ましくは98%以上、より好ましくは99%以上の同一性を有するヌクレオチド配列
からなる群から選択される、前記ヌクレオチド配列。 - 請求項1に記載のヌクレオチド配列を含む、ベクター。
- 宿主細胞であって、請求項2に記載のベクターを含むか、またはその染色体に組み込まれた請求項1に記載の外因性ヌクレオチド配列を有する、前記宿主細胞。
- 視神経関連疾患の治療のための調製物または組成物の調製における、請求項2に記載のベクターの使用。
- 前記調製物または組成物が、
(a)細胞の抗炎症反応または抗酸化反応を活性化すること、
(b)神経節細胞の生存率を高めること、
(c)神経節細胞のアポトーシスを防止するまたは遅延させること、
(d)網膜神経節細胞におけるNrf2遺伝子の安定した高い発現を引き起こすこと、及び
(e)疾患細胞からフリーラジカルを除去すること
からなる群から選択される1つ以上の項目のためにも使用される、請求項4に記載の使用。 - 前記視神経関連疾患が視神経損傷を含む、請求項4に記載の使用。
- 前記視神経関連疾患が、緑内障、常染色体優性視神経萎縮症(DOA)、レーバー遺伝性視神経症(LHON)、虚血性視神経症、またはそれらの組み合わせからなる群から選択される、請求項4に記載の使用。
- (a)請求項2に記載のベクターと、(b)薬学的に許容される担体または賦形剤と、を含む、医薬調製物。
- 前記医薬調製物中の前記ベクターの含有量が1×109~1×1016ウイルス/ml、好ましくは1×1010~1×1012ウイルス/mlである、請求項8に記載の医薬調製物。
- 組換えヒト核因子E2関連因子2(Nrf2)タンパク質を調製する方法であって、請求項3に記載の宿主細胞を培養して、前記組換えヒト核因子E2関連因子2(Nrf2)タンパク質を得るステップを含む、前記方法。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2020/082162 WO2021195876A1 (zh) | 2020-03-30 | 2020-03-30 | 一种人核因子e2相关因子2的表达载体及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2023528139A true JP2023528139A (ja) | 2023-07-04 |
Family
ID=77927115
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022559360A Pending JP2023528139A (ja) | 2020-03-30 | 2020-03-30 | ヒト核因子e2関連因子2の発現ベクター及び発現ベクターの適用 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20240209391A1 (ja) |
EP (1) | EP4163375A4 (ja) |
JP (1) | JP2023528139A (ja) |
KR (1) | KR20230015891A (ja) |
CN (1) | CN115279906A (ja) |
AU (1) | AU2020440834A1 (ja) |
BR (1) | BR112022018193A2 (ja) |
CA (1) | CA3173999A1 (ja) |
MX (1) | MX2022012209A (ja) |
WO (1) | WO2021195876A1 (ja) |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
WO1991018088A1 (en) | 1990-05-23 | 1991-11-28 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Adeno-associated virus (aav)-based eucaryotic vectors |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
US6989264B2 (en) | 1997-09-05 | 2006-01-24 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
JP4827353B2 (ja) | 1999-08-09 | 2011-11-30 | ターゲティッド ジェネティクス コーポレイション | 鎖内塩基対を形成するような配列の設計による、組換えウイルスベクターからの一本鎖の異種ヌクレオチド配列の発現の増大 |
DE602004005617T2 (de) * | 2003-12-22 | 2007-12-13 | Alcon Inc. | Mittel zur behandlung von glaukomatöser retinopathie und optischer neuropathie |
US10054583B2 (en) * | 2012-10-10 | 2018-08-21 | Temple University Of The Commonwealth System Of Higher Education | Nuclear factor-erythroid 2 related factor 2 (NRF2) biosensors and modulators of NRF2 |
WO2016039359A1 (ja) * | 2014-09-10 | 2016-03-17 | 第一三共株式会社 | 眼疾患治療用及び予防用徐放性医薬組成物 |
US11879133B2 (en) * | 2017-04-24 | 2024-01-23 | The Trustees Of The University Of Pennsylvania | Gene therapy for ocular disorders |
CN109055428A (zh) * | 2018-09-19 | 2018-12-21 | 上海市第人民医院 | 一种重组腺相关病毒载体及其制备方法与应用 |
-
2020
- 2020-03-30 CN CN202080098441.3A patent/CN115279906A/zh active Pending
- 2020-03-30 US US17/914,871 patent/US20240209391A1/en active Pending
- 2020-03-30 MX MX2022012209A patent/MX2022012209A/es unknown
- 2020-03-30 JP JP2022559360A patent/JP2023528139A/ja active Pending
- 2020-03-30 WO PCT/CN2020/082162 patent/WO2021195876A1/zh unknown
- 2020-03-30 CA CA3173999A patent/CA3173999A1/en active Pending
- 2020-03-30 KR KR1020227036975A patent/KR20230015891A/ko unknown
- 2020-03-30 BR BR112022018193A patent/BR112022018193A2/pt unknown
- 2020-03-30 EP EP20928296.1A patent/EP4163375A4/en active Pending
- 2020-03-30 AU AU2020440834A patent/AU2020440834A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2022012209A (es) | 2022-10-27 |
CN115279906A (zh) | 2022-11-01 |
KR20230015891A (ko) | 2023-01-31 |
EP4163375A4 (en) | 2024-01-03 |
US20240209391A1 (en) | 2024-06-27 |
AU2020440834A1 (en) | 2022-09-22 |
CA3173999A1 (en) | 2021-10-07 |
EP4163375A1 (en) | 2023-04-12 |
BR112022018193A2 (pt) | 2022-10-25 |
WO2021195876A1 (zh) | 2021-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111621502B (zh) | 视网膜劈裂蛋白的编码序列、其表达载体构建及其应用 | |
US11970519B2 (en) | Gene therapy vector for treating retinitis pigmentosa disease | |
US11459584B2 (en) | Gene sequence of recombinant human type II mitochondrial dynein-like GTPase and uses thereof | |
CN112029773B (zh) | 编码bdnf的核酸及其应用 | |
JP7289306B2 (ja) | 網膜障害を治療するための組成物及び方法 | |
WO2020077756A1 (zh) | Nd4蛋白的编码序列及其应用 | |
WO2020010491A1 (zh) | 编码人nadh脱氢酶亚单位4蛋白的核酸及其应用 | |
CN113025633A (zh) | 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用 | |
CN111926021B (zh) | 重组人norrin胱氨酸结生长因子表达载体及其应用 | |
WO2023198050A1 (zh) | 一种融合型腺相关病毒及其应用 | |
WO2020000641A1 (zh) | 编码人nadh脱氢酶亚单位蛋白的核酸及其应用 | |
EP4163375A1 (en) | Expression vector of human nuclear factor e2-related factor 2 and application of expression vector | |
CN111518813B (zh) | 视紫红质的编码序列、其表达载体构建及其应用 | |
CN111909935B (zh) | 重组人卷曲蛋白受体4(fzd4)的表达载体及其应用 | |
WO2024083013A1 (zh) | 人线粒体动力蛋白样gtp酶及应用 | |
JP7495756B2 (ja) | 医薬の製造におけるCYP4V2およびRdCVFの使用 | |
CN110699367B (zh) | 编码人nadh脱氢酶亚单位4蛋白的核酸及其应用 | |
CA3217750A1 (en) | Kcnv2 variants and their use | |
WO2022129543A1 (en) | Gene therapy for treating usher syndrome | |
JP2022523050A (ja) | 合理的設計により増強された新規なaavウイルスによる網膜における高効率の形質導入および側方への広がり |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230315 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230315 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240227 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240229 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240522 |